SecBot SecBot
8-K ·Filed Nov 5, 2026

SOLV

Solventum Corp
BULLISH
Impact 6/10
Horizonweeks Processed11d 5h ago SEC0001964738-26-000055
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The raised adjusted EPS guidance and completion of ERP cutovers signal improving operational execution. Monitor the Q4 earnings call for organic sales growth trajectory and progress on the planned separation of the Health Information Systems business.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$90.38
T+0 close · Nov 5, 2026 · via day close
Latest settled
−1.44%
T+5 · $89.08
Vs SPY
−4.03%
α at T+5
Next horizon
T+20
in 20d
  1. T+0 · Nov 6 $90.38entry
  2. T+1 · 8d ago +0.06%α −2.31% · $90.43
  3. T+5 · 4d ago −1.44%α −4.03% · $89.08
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Solventum reported Q3 2026 adjusted EPS of $1.45, beating the $1.34 consensus, on revenue of $1.949B which was slightly above the $1.93B estimate. Reported sales fell 7.0% (organic -2.8%) due to a 630bps ERP cutover reversal, but the company raised full-year adjusted EPS guidance to $7.20-$7.30 from $7.10-$7.20 and expects organic sales growth toward the high end of +2.5% to +3.0%.

Key Financial Metrics

EPS (Adj.)
$1.45
est $1.34 · +8.2% · GAAP: $-0.07
Revenue
$1.9B
est $1.9B · +1.0% · -7.0% YoY
Rating
beat
Free Cash Flow
$97.0M
Gross Margin
54.5%

Key Facts

  • Q3 2026 adjusted EPS of $1.45 vs consensus $1.34, a beat of 8.2%
  • Q3 2026 revenue of $1.949B vs consensus $1.93B
  • Reported sales decreased 7.0%; organic sales decreased 2.8% due to 630bps ERP cutover reversal
  • Full-year adjusted EPS guidance raised to $7.20-$7.30 from $7.10-$7.20
  • Full-year organic sales growth expected toward high end of +2.5% to +3.0% range
  • Operating cash flow of $177M and free cash flow of $97M in Q3
  • GAAP diluted EPS was $(0.07) due to restructuring and separation costs
  • Adjusted operating income margin was 19.9%, down 70bps YoY
  • Health Information Systems segment organic growth of 4.4%; MedSurg organic decline of 2.8%
  • Exited 90% of 3M transition service agreements; ERP cutovers complete

Financial Impact

Adjusted EPS beat consensus by $0.11 (8.2%); full-year adjusted EPS guidance raised by $0.10 at the midpoint

adjusted EPSrevenueguidancefree cash flow

Segment Breakdown

SegmentRevenueGrowth
MedSurg$1.2B+0.4%
Dental Solutions$317.0M-6.7%
Health Information Systems$356.0M+3.3%

Risk Factors

  • Reported revenue decline of 7.0% and GAAP net loss of $(12M) due to restructuring and separation costs
  • Adjusted operating margin contracted 70bps YoY to 19.9%
  • Dental Solutions segment organic sales declined 7.4%
  • Free cash flow for the first nine months was negative $(32M)

Market Snapshot

Exchange
NYSE
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
59% bullish (22 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001964738-26-000055
Document: solv-20261105.htm0001964738-26-000055
Document: 0001964738-26-000055-index-headers.html0001964738-26-000055
Document: 0001964738-26-000055-index.html0001964738-26-000055
Document: 0001964738-26-000055.txt0001964738-26-000055
8-K Data (Synthetic)0001964738-26-000055

US Market Status

Market Closed · Opens Wed (12h 12m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026